Development of automated brightfield double <it>In Situ </it>hybridization (BDISH) application for <it>HER2 g</it>ene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color <it>HER2 </it>fluorescence <it>In Situ </it>hybridization (FISH)
<p>Abstract</p> <p>Background</p> <p>Human epidermal growth factor receptor 2 (<it>HER2</it>) fluorescence <it>in situ </it>hybridization (FISH) is a quantitative assay for selecting breast cancer patients for trastuzumab therapy. However, curren...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-10-01
|
| Series: | Diagnostic Pathology |
| Online Access: | http://www.diagnosticpathology.org/content/3/1/41 |